
PRIME TECH

PRINT MEDICAL TECHNOLOGY

PROFILE

Biotech Company.
Founded: May 2018.
Pre-Money valuation: 10MUSD.
Investment: 0,5 MUSD.

PRIME has developed a **technology platform** which prints drugs into films in a more affordable and stable way, becoming a method for buccal drug administration. By replacing injections, it is expected to improve patients' compliance to treatments while increasing pharmaceutical industry's sales.

OPPORTUNITY

Non-compliance with injection treatments is increasing among patients with type 2 Diabetes due to needle fears. By 2030, this will represent an increase of USD 2.5 trillion (US only) in costs. Moreover, 75% of insulin-dependent patients are not currently treated.

SOLUTION

A needle-free technology will increase sales by improving patients' compliance with their treatments (up to 200 million insulin-dependent patients not currently served). This will also expand the current portfolio patent coverage of pharma companies. Besides, printed human insulin production is nearly 75% less expensive than many other commercially available insulin varieties.

TECHNOLOGY

Patented technology in Chile (CL59.032) and patent pending technology in European Union (EP3403643) and US (US2019015320), allows biologically charged nanosuspensions to be printed into commercially available buccal films.


- Precise printed dose.
- High permeation through buccal epithelia.


TECH BASED

STARTUP



KNOWHUB
Technology
Transfer
Chile





MARKET

Market size: USD 1.244 million (2018).

CAGR: 6,4%.


Segment: Oral Thin Films.

Expected market size: USD 1.694 million (2026).

BUSINESS MODEL

Two potential business models:

1. **PriMe** will license its technology to pharma industry.
2. **PriMe** will strengthen its in-house printing capacity and become a film supplier to pharma. Work will be initially focused on Insulin, although this technology will eventually include other peptides and small molecules.



METRICS

- 20-40% *ex vivo* bioavailability
- Subcutaneous-like glycemia decrease in animal model after film administration

TEAM



Juanita Castañeda
CEO Microbiologist



Enzo Pantoja
CEO, Microbiologist



Javier Morales
CTO & Inventor, Pharma Science Ph.D.



Miguel Jara
Researcher Pharma Chemist



Sebastián Luco
Legal Affairs Lawyer



Carolina Cortés
Operations Biotech

Contact: Jovanka Trebotich Zuñiga

Technology Transfer Coordinator

jovanka.trebotich@knowhub.cl

www.knowhub.cl

Phone +56 22 3895600

